Evan Lewis
8Patents
4h-index
15Co-inventors
54Inventor score
Filing activity: Jun 11, 2001 → Sep 27, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7737112B2 | Composition for enzyme inhibition | Emerging Cross-Sectional Technologies | 53 | Active |
| US7425541B2 | Enzyme-cleavable prodrug compounds | Human Necessities | 19 | Expired |
| US10159746B2 | Cyclodextrin complexation methods for formulating peptide proteasome inhibitors | Performing Operations; Transporting | 13 | Active |
| US8034787B2 | Enzyme-cleavable prodrug compounds | Human Necessities | 5 | Active |
| US10836756B2 | Crystalline salts of peptide epoxyketone immunoproteasome inhibitor | Chemistry; Metallurgy | 0 | Active |
| US11479548B2 | Crystalline salts of peptide epoxyketone immunoproteasome inhibitor | Chemistry; Metallurgy | 0 | Active |
| US12357638B2 | Immunoproteasome inhibitor formulations | Human Necessities | 0 | Active |
| US11891383B2 | Crystalline salts of peptide epoxyketone immunoproteasome inhibitor | Chemistry; Metallurgy | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.